Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
Portfolio Pulse from
Longeveron Inc. reported a 237% increase in 2024 revenue to $2.4 million, driven by contract manufacturing and demand for the Bahamas Registry Trial. The company is progressing with its Phase 2b trial for Lomecel-B™ in Hypoplastic Left Heart Syndrome, with over 90% enrollment. A BLA submission is anticipated in 2026, pending trial success.
February 28, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longeveron Inc. reported a significant revenue increase of 237% for 2024, attributed to contract manufacturing and increased trial demand. The Phase 2b trial for Lomecel-B™ in HLHS is nearing full enrollment, with a BLA submission expected in 2026 if successful.
The substantial revenue growth and progress in clinical trials are positive indicators for Longeveron's future prospects. The nearing completion of the Phase 2b trial and potential BLA submission could lead to significant advancements in their product pipeline, positively impacting stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100